This all makes sense, doesn't it? We know that SARS-CoV-2 causes an incredible response from the victim in the way of inflammation of tissues. The virus is also indiscriminate in the type of tissue it effects. But, we also know it has an affinity for the nervous system and in that lies the body's inflammation response to stop the virus.
The woman is recovering and that is exceptionally good news in relation to side effects of this vaccine. She is going to be okay. Not all the people effected by COVID-19's inflammation response survived to talk about it. She is also recovering quickly.
So, this will be considered a side effect of the vaccine. More over, since this is such a severe response the team at AstraZeneca will probably review all the data they have accumulated to this point and decide if the vaccine needs to be adjusted or this is the best it will be and the side effect in this case needs to be regarded as a potential problem for the people receiving the vaccine.
It is my guess, the researchers will double their efforts to examine all the data and bring this side effect under control in the final version of the vaccine. That could mean the vaccine needs a co-partner that will protect from extreme inflammation while still providing significant protection from SARS-CoV-2. That is a tough one because steroids are not good partners to producing a strong antibody response.
This is a prime example of the significant value of the third step in preparing a vaccine for use by everyone. The third trial does bring a better focus to widespread use. It is a very important trial.
By Adam Feuerstein
The participant (click here) who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning.
The woman’s diagnosis has not been confirmed yet, but she is improving and will likely be discharged from the hospital as early as Wednesday, Soriot said.
The board tasked with overseeing the data and safety components of the AstraZeneca clinical trials confirmed that the participant was injected with the company’s Covid-19 vaccine and not a placebo, Soriot said on the conference call, which was set up by the investment bank J.P. Morgan....
